TARA News and Press, ArTara Therapeutics Inc. From 11/03/23

2023-11-03 12:29:17 ET Protara Therapeutics ( NASDAQ: TARA ) on Friday filed a prospectus for a mixed securities shelf offering of up to $300M. This prospectus is not an offer to sell these securities. Shares of TARA rose 17.2% . SEC Filing For furth...

2023-11-03 10:22:52 ET More on Protara Therapeutics Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings data for Protara Therapeutics Financial information for Protara Therapeutics For further details see: Protara Therapeutics ...

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS Company initiate...

Protara Therapeutics Inc. (TARA) is expected to report $-1.1 for Q3 2023

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in the Phase 2 STARBORN-1 trial evaluating TARA-002, a...

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that dosing is now underway in its Phase 1b/2 ADVANCED-2 trial evaluating intrave...

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investmen...

2023-08-03 13:55:56 ET Protara Therapeutics press release ( NASDAQ: TARA ): Q2 GAAP EPS of -$1.00. Cash, cash equivalents and investments of $80M as of June 30, 2023 expected to fund operations into 2025 Company plans to initiate Phase 2 trial of TARA-002 in Lymphatic ...

Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 Company plans to commence dosing in ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS in 4Q...

Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trial Company advancing NMIBC clinical development program, with Phase 1b/2 trial in BCG-unresponsive CIS patients and in BCG-naïve and BCG-expose...